Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey
Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey
复制标题
DOI：
10.1038/clpt.2011.306
复制
发表时间：
2012-03-01
影响因子：
6.7
通讯作者：
Frueh, F. W.
中科院分区：
文献类型：
--
作者：
Stanek, E. J.;Sanders, C. L.;Frueh, F. W.
为了制定一个衡量美国医生对药物基因组学检测的知识水平和使用程度的基准，我们进行了一项匿名的、横断面的、基于传真的全国性调查。在接受调查问卷的397，832名医生中，有10，303名（3%）完成并返回了调查问卷;受访者代表了整个美国医生人群。采用X-2和多变量logistic回归分析评估与决定测试相关的因素。总体而言，97.6%的医生同意遗传变异可能会影响药物反应，但只有10.3%的医生对药物基因组学检测有充分的了解。只有12.9%的医生在过去6个月内进行了检查，26.4%的医生预计在未来6个月内进行检查。早期和未来采用测试的人更有可能接受过药物基因组学的培训，但只有29.0%的医生接受过该领域的任何教育。我们的研究结果强调需要更有效的医生教育的临床价值，可用性和解释药物基因组学测试。
To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross-sectional, fax-based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303 (3%) completed and returned it; the respondents were representative of the overall US physician population. The factors associated with the decision to test were evaluated using X-2 and multivariate logistic regression. Overall, 97.6% of responding physicians agreed that genetic variations may influence drug response, but only 10.3% felt adequately informed about pharmacogenomic testing. Only 12.9% of physicians had ordered a test in the previous 6 months, and 26.4% anticipated ordering a test in the next 6 months. Early and future adopters of testing were more likely to have received training in pharmacogenomics, but only 29.0% of physicians overall had received any education in the field. Our findings highlight the need for more effective physician education on the clinical value, availability, and interpretation of pharmacogenomic tests.